Shailendra Asthana

Dr. Shailendra Asthana


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2020 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
LMLovika Mittal
Lovika Mittal
AKAnita Kumari
Anita Kumari
MSMitul Srivastava
Mitul Srivastava
MSMrityunjay Singh
Mrityunjay Singh
SAShailendra Asthana
Shailendra Asthana
The pandemic caused by novel coronavirus disease 2019 (COVID-19) infecting millions of populations worldwide and counting, has demanded quick and potential therapeutic strategies. Current approved drugs or molecules under clinical trials can be a good pool for repurposing through in-silico techniques to quickly identify promising drug candidates. The structural information of recently released crystal structures of main protease (Mpro) in APO and complex with inhibitors, N3, and 13b molecules was utilized to explore the binding site architecture through Molecular dynamics (MD) simulations. The stable state of Mpro was used to conduct extensive virtual screening of the aforementioned drug pool. Considering the recent success of HIV protease molecules, we also used anti-protease molecules for drug repurposing purposes. The identified top hits were further evaluated through MD simulations followed by the binding free energy calculations using MM-GBSA. Interestingly, in our screening, several promising drugs stand out as potential inhibitors of Mpro. However, based on control (N3 and 13b), we have identified six potential molecules, Leupeptin Hemisulphate, Pepstatin A, Nelfinavir, Birinapant, Lypression and Octreotide which have shown the reasonably significant MM-GBSA score. Further insight shows that the molecules form stable interactions with hot-spot residues, that are mainly conserved and can be targeted for structure- and pharmacophore-based designing. The pharmacokinetic annotations and therapeutic importance have suggested that these molecules possess drug-like properties and pave their way for in-vitro studies.

1 January 2020 in International Journal of Biological Sciences
Verified
Journal Article
Open access
AKAnita Kumari
Anita Kumari
DPDharam Pal Pathak
Dharam Pal Pathak
SAShailendra Asthana
Shailendra Asthana
Perturbation in lipid homeostasis is one of the major bottlenecks in metabolic diseases, especially Non-alcoholic Fatty Liver Disease (NAFLD), which has emerged as a leading global cause of chronic liver disease. The bile acids (BAs) and their derivatives exert a variety of metabolic effects through complex and intertwined pathways, thus becoming the attractive target for metabolic syndrome treatment. To modulate the lipid homeostasis, the role of BAs, turn out to be paramount as it is essential for the absorption, transport of dietary lipids, regulation of metabolic enzymes and transporters that are essential for lipid modulation, flux, and excretion. The synthesis and transport of BAs (conjugated and unconjugated) is chiefly controlled by nuclear receptors and the uptake of long-chain fatty acids (LCFA) and BA conjugation via transporters. Among them, from in-vivo studies, farnesoid X receptor (FXR) and liver-specific fatty acid transport protein 5 (FATP5) have shown convincing evidence for their key roles in lipid homeostasis and reversal of fatty liver disease substantially. BAs have a wider range of biological effects as they are identified as modulators for FXR and FATP5 both and therefore hold a significant promise for altering the lipid content in the treatment of a metabolic disorder. BAs also have received noteworthy interest in drug delivery research due to its peculiar physicochemical properties and biocompatibility. Here, we are highlighting the connecting possibility of BAs as an agonist for FXR and antagonist for FATP5, paving an avenue to target them for designing synthetic small molecules for lipid homeostasis.

12 January 2021 in Journal of Chemical Information and Modeling
Verified
Journal Article
Closed access
LMLovika Mittal
Lovika Mittal
MSMitul Srivastava
Mitul Srivastava
AKAnita Kumari
Anita Kumari
RTRajiv K. Tonk
Rajiv K. Tonk
AAAmit Awasthi
Amit Awasthi
SAShailendra Asthana
Shailendra Asthana

28 September 2018 in Oncotarget
Verified
Journal Article
Open access
PDF file
MSMitul Srivastava
Mitul Srivastava
CSCharu Suri
Charu Suri
MSMrityunjay Singh
Mrityunjay Singh
RMRajani Mathur
Rajani Mathur
SAShailendra Asthana
Shailendra Asthana
Oncotarget | https://doi.org/10.18632/oncotarget.26136 Mitul Srivastava, Charu Suri, Mrityunjay Singh, Rajani Mathur, Shailendra Asthana Molecular dynamics simulation reveals the possible druggable hotspots of USP7

10 October 2023 in Cancers
Verified
Journal Article
Open access
PDF file
KAKirti Agrawal
Kirti Agrawal
SAShailendra Asthana
Shailendra Asthana
Dhruv KumarDhruv Kumar
Dhruv Kumar
Brain cancer is known as one of the deadliest cancers globally. One of the causative factors is the imbalance between oxidative and antioxidant activities in the body, which is referred to as oxidative stress (OS). As part of regular metabolism, oxygen is reduced by electrons, resulting in the creation of numerous reactive oxygen species (ROS). Inflammation is intricately associated with the generation of OS, leading to the increased production and accumulation of reactive oxygen and nitrogen species (RONS). Glioma stands out as one of the most common malignant tumors affecting the central nervous system (CNS), characterized by changes in the redox balance. Brain cancer cells exhibit inherent resistance to most conventional treatments, primarily due to the distinctive tumor microenvironment. Oxidative stress (OS) plays a crucial role in the development of various brain-related malignancies, such as glioblastoma multiforme (GBM) and medulloblastoma, where OS significantly disrupts the normal homeostasis of the brain. In this review, we provide in-depth descriptions of prospective targets and therapeutics, along with an assessment of OS and its impact on brain cancer metabolism. We also discuss targeted therapies.

1 November 2021 in Archives of Biochemistry and Biophysics
Verified
Journal Article
Closed access
LMLovika Mittal
Lovika Mittal
RTRajiv K. Tonk
Rajiv K. Tonk
AAAmit Awasthi
Amit Awasthi
SAShailendra Asthana
Shailendra Asthana